Gestational Trophoblastic Disease - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512244706

Publication Date:

December 6, 2024

Pages:

104

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Gestational trophoblastic disease (GTD) is听a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
The global market for Gestational Trophoblastic Disease was estimated to be worth US$ 1940 million in 2023 and is forecast to a readjusted size of US$ 2587.6 million by 2030 with a CAGR of 4.3% during the forecast period 2024-2030
The global gestational trophoblastic disease (GTD) market refers to the market for diagnostic tests, treatments, and management strategies aimed at addressing GTD, a group of rare tumors that arise in the cells of the placenta during pregnancy. GTD includes conditions such as hydatidiform mole, gestational trophoblastic neoplasia, and choriocarcinoma.
The market for GTD is driven by several factors, including the increasing incidence of these diseases, advancements in diagnostic techniques, and improvements in treatment options. Early detection and accurate diagnosis are crucial for effective management of GTD. Diagnostic methods include ultrasound, human chorionic gonadotropin (hCG) measurement, and histopathological examination.
The primary treatment for GTD is the surgical removal of the affected tissue, which is often followed by chemotherapy in cases of gestational trophoblastic neoplasia and choriocarcinoma. Methotrexate is commonly used as a chemotherapy drug, and other chemotherapeutic agents may also be employed depending on the stage and type of the disease. In cases of high-risk or resistant GTD, additional treatments such as radiation therapy may be recommended.
Geographically, North America and Europe hold a significant share in the global GTD market, primarily due to factors such as well-established healthcare infrastructure, advanced diagnostic technologies, and increased awareness about GTD. Asia-Pacific is also experiencing growth in the GTD market, attributed to factors such as rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about women鈥檚 health.
Key players in the global GTD market include pharmaceutical companies, diagnostic test manufacturers, and healthcare providers specializing in women鈥檚 health. These companies focus on developing innovative diagnostic tests, drugs, and treatment protocols to improve patient outcomes and ensure better management of GTD.
However, challenges in the GTD market include the rarity of these diseases, leading to limited awareness and expertise among healthcare professionals, as well as the potential for complications and the need for individualized treatment approaches. Additionally, the emotional and psychological impact of GTD on patients and their families is an area that requires attention and support.
In summary, the global gestational trophoblastic disease market is driven by factors such as the increasing incidence of these rare tumors, advancements in diagnostic techniques, and improvements in treatment options. North America and Europe currently lead the market, but Asia-Pacific is witnessing growth. Key players in the market continue to invest in research and development to improve diagnostic accuracy, develop targeted therapies, and ensure optimal management of GTD.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gestational Trophoblastic Disease, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gestational Trophoblastic Disease by region & country, by Type, and by Application.
The Gestational Trophoblastic Disease market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gestational Trophoblastic Disease.
麻豆原创 Segmentation
By Company
Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma
Segment by Type:
Chemotherapy
Surgery
Radiation Therapy
Others
Segment by Application
Hospitals
Clinics
Cancer Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gestational Trophoblastic Disease manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gestational Trophoblastic Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gestational Trophoblastic Disease in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Gestational Trophoblastic Disease Product Introduction
1.2 Global Gestational Trophoblastic Disease 麻豆原创 Size Forecast
1.3 Gestational Trophoblastic Disease 麻豆原创 Trends & Drivers
1.3.1 Gestational Trophoblastic Disease Industry Trends
1.3.2 Gestational Trophoblastic Disease 麻豆原创 Drivers & Opportunity
1.3.3 Gestational Trophoblastic Disease 麻豆原创 Challenges
1.3.4 Gestational Trophoblastic Disease 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gestational Trophoblastic Disease Players Revenue Ranking (2023)
2.2 Global Gestational Trophoblastic Disease Revenue by Company (2019-2024)
2.3 Key Companies Gestational Trophoblastic Disease Manufacturing Base Distribution and Headquarters
2.4 Key Companies Gestational Trophoblastic Disease Product Offered
2.5 Key Companies Time to Begin Mass Production of Gestational Trophoblastic Disease
2.6 Gestational Trophoblastic Disease 麻豆原创 Competitive Analysis
2.6.1 Gestational Trophoblastic Disease 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Gestational Trophoblastic Disease Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gestational Trophoblastic Disease as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemotherapy
3.1.2 Surgery
3.1.3 Radiation Therapy
3.1.4 Others
3.2 Global Gestational Trophoblastic Disease Sales Value by Type
3.2.1 Global Gestational Trophoblastic Disease Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gestational Trophoblastic Disease Sales Value, by Type (2019-2030)
3.2.3 Global Gestational Trophoblastic Disease Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Cancer Research Institutes
4.1.4 Others
4.2 Global Gestational Trophoblastic Disease Sales Value by Application
4.2.1 Global Gestational Trophoblastic Disease Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gestational Trophoblastic Disease Sales Value, by Application (2019-2030)
4.2.3 Global Gestational Trophoblastic Disease Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Gestational Trophoblastic Disease Sales Value by Region
5.1.1 Global Gestational Trophoblastic Disease Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gestational Trophoblastic Disease Sales Value by Region (2019-2024)
5.1.3 Global Gestational Trophoblastic Disease Sales Value by Region (2025-2030)
5.1.4 Global Gestational Trophoblastic Disease Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Gestational Trophoblastic Disease Sales Value, 2019-2030
5.2.2 North America Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Gestational Trophoblastic Disease Sales Value, 2019-2030
5.3.2 Europe Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Gestational Trophoblastic Disease Sales Value, 2019-2030
5.4.2 Asia Pacific Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Gestational Trophoblastic Disease Sales Value, 2019-2030
5.5.2 South America Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Gestational Trophoblastic Disease Sales Value, 2019-2030
5.6.2 Middle East & Africa Gestational Trophoblastic Disease Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gestational Trophoblastic Disease Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gestational Trophoblastic Disease Sales Value
6.3 United States
6.3.1 United States Gestational Trophoblastic Disease Sales Value, 2019-2030
6.3.2 United States Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gestational Trophoblastic Disease Sales Value, 2019-2030
6.4.2 Europe Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gestational Trophoblastic Disease Sales Value, 2019-2030
6.5.2 China Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gestational Trophoblastic Disease Sales Value, 2019-2030
6.6.2 Japan Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gestational Trophoblastic Disease Sales Value, 2019-2030
6.7.2 South Korea Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gestational Trophoblastic Disease Sales Value, 2019-2030
6.8.2 Southeast Asia Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gestational Trophoblastic Disease Sales Value, 2019-2030
6.9.2 India Gestational Trophoblastic Disease Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gestational Trophoblastic Disease Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bristol Myers Squibb
7.1.1 Bristol Myers Squibb Profile
7.1.2 Bristol Myers Squibb Main Business
7.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Products, Services and Solutions
7.1.4 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.1.5 Bristol Myers Squibb Recent Developments
7.2 Antares Pharma
7.2.1 Antares Pharma Profile
7.2.2 Antares Pharma Main Business
7.2.3 Antares Pharma Gestational Trophoblastic Disease Products, Services and Solutions
7.2.4 Antares Pharma Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.2.5 Antares Pharma Recent Developments
7.3 Novartis AG
7.3.1 Novartis AG Profile
7.3.2 Novartis AG Main Business
7.3.3 Novartis AG Gestational Trophoblastic Disease Products, Services and Solutions
7.3.4 Novartis AG Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.3.5 Accord Healthcare Limited Recent Developments
7.4 Accord Healthcare Limited
7.4.1 Accord Healthcare Limited Profile
7.4.2 Accord Healthcare Limited Main Business
7.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Products, Services and Solutions
7.4.4 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.4.5 Accord Healthcare Limited Recent Developments
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Profile
7.5.2 Eli Lilly and Company Main Business
7.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Products, Services and Solutions
7.5.4 Eli Lilly and Company Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.5.5 Eli Lilly and Company Recent Developments
7.6 Sanofi
7.6.1 Sanofi Profile
7.6.2 Sanofi Main Business
7.6.3 Sanofi Gestational Trophoblastic Disease Products, Services and Solutions
7.6.4 Sanofi Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.6.5 Sanofi Recent Developments
7.7 Bayer AG
7.7.1 Bayer AG Profile
7.7.2 Bayer AG Main Business
7.7.3 Bayer AG Gestational Trophoblastic Disease Products, Services and Solutions
7.7.4 Bayer AG Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.7.5 Bayer AG Recent Developments
7.8 Amgen
7.8.1 Amgen Profile
7.8.2 Amgen Main Business
7.8.3 Amgen Gestational Trophoblastic Disease Products, Services and Solutions
7.8.4 Amgen Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.8.5 Amgen Recent Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Profile
7.9.2 Merck KGaA Main Business
7.9.3 Merck KGaA Gestational Trophoblastic Disease Products, Services and Solutions
7.9.4 Merck KGaA Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.9.5 Merck KGaA Recent Developments
7.10 Teva Pharmaceuticals
7.10.1 Teva Pharmaceuticals Profile
7.10.2 Teva Pharmaceuticals Main Business
7.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Products, Services and Solutions
7.10.4 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.10.5 Teva Pharmaceuticals Recent Developments
7.11 B.P Pharma
7.11.1 B.P Pharma Profile
7.11.2 B.P Pharma Main Business
7.11.3 B.P Pharma Gestational Trophoblastic Disease Products, Services and Solutions
7.11.4 B.P Pharma Gestational Trophoblastic Disease Revenue (US$ Million) & (2019-2024)
7.11.5 B.P Pharma Recent Developments
8 Industry Chain Analysis
8.1 Gestational Trophoblastic Disease Industrial Chain
8.2 Gestational Trophoblastic Disease Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gestational Trophoblastic Disease Sales Model
8.5.2 Sales Channel
8.5.3 Gestational Trophoblastic Disease Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.